Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

47.77 +0.26 (+0.55%)
Streaming Delayed Price Updated: 10:52 AM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,851,391
Open 47.59
Bid (Size) 47.77 (3)
Ask (Size) 47.78 (6)
Prev. Close 47.51
Today's Range 47.46 - 47.92
52wk Range 39.35 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 5.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Large-Cap Stocks Skating on Thin Ice
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga

Performance

YTD
-15.9%
-15.9%
1 Month
-2.1%
-2.1%
3 Month
-19.8%
-19.8%
6 Month
-15.5%
-15.5%
1 Year
+15.7%
+15.7%

More News

Read More
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering
Via Chartmill
FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers
Via Benzinga
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
From Bristol Myers Squibb
Via Business Wire
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Via Investor's Business Daily
Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2B Cancer Drug
Via Benzinga
Topics Fraud Lawsuit
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A Potentially Undervalued Stock Worth Considering
Via Chartmill
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Q1 Earnings Outperformers: Eli Lilly (NYSE:LLY) And The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bristol Myers’ Cancer Drug Data Fuels Retail Buzz, But Bearish Sentiment Lingers
Via Stocktwits
Top S&P500 movers in Monday's session
Via Chartmill
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
From Bristol Myers Squibb
Via Business Wire
2 Beaten-Down Dividend Stocks to Buy Right Now
Via The Motley Fool
Topics Economy World Trade
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
Via Benzinga
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
From Bristol Myers Squibb
Via Business Wire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
Via FinancialNewsMedia
Topics Artificial Intelligence
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus
From Philogen S.p.A.
Via GlobeNewswire
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Via The Motley Fool
Topics Intellectual Property
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A High-Yield Dividend Stock Worth Considering
Via Chartmill
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Via The Motley Fool
Topics Intellectual Property Retirement
1 Cash-Producing Stock to Own for Decades and 2 to Think Twice About
Via StockStory

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 47.77
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 07/02/25 10:52 AM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 106.15B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 106B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.